Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company’s lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.
2011
87
LTM Revenue n/a
LTM EBITDA -$124M
$232M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Celcuity has a last 12-month revenue of n/a and a last 12-month EBITDA of -$124M.
In the most recent fiscal year, Celcuity achieved revenue of n/a and an EBITDA of -$101M.
Celcuity expects next 12-month revenue of XXX   and NTM EBITDA of XXX
See Celcuity valuation multiples based on analyst estimatesFY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
---|---|---|---|---|---|
Revenue | n/a | n/a | XXX | XXX | XXX |
Gross Profit | n/a | n/a | XXX | XXX | XXX |
Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
EBITDA | -$58.3M | -$101M | XXX | XXX | XXX |
EBITDA Margin | -Infinity% | -Infinity% | XXX | XXX | XXX |
Net Profit | -$40.4M | -$63.8M | XXX | XXX | XXX |
Net Margin | -Infinity% | -Infinity% | XXX | XXX | XXX |
Net Debt | $10.4M | $6.4M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Celcuity's stock price is $10.
Celcuity has current market cap of $369M, and EV of $232M.
See Celcuity trading valuation dataEV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
---|---|---|---|---|---|---|
$232M | $369M | XXX | XXX | XXX | XXX | $-3.00 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Celcuity has market cap of $369M and EV of $232M.
Celcuity's trades at n/a LTM EV/Revenue multiple, and -1.9x LTM EBITDA.
Analysts estimate Celcuity's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Celcuity and 10K+ public compsFY 2024 | FY 2025E | FY 2026E | FY 2027E | |
---|---|---|---|---|
EV | $232M | XXX | XXX | XXX |
EV/Revenue | n/a | XXX | XXX | XXX |
EV/EBITDA | -2.3x | XXX | XXX | XXX |
P/E | -3.3x | XXX | XXX | XXX |
P/E/Growth | n/a | XXX | XXX | XXX |
EV/FCF | -2.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpCelcuity's NTM/LTM revenue growth is Infinity%
Celcuity's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $1.3M for the same period.
Over next 12 months, Celcuity's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Celcuity's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Celcuity and other 10K+ public compsFY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
---|---|---|---|---|---|
Revenue Growth | n/a | XXX | XXX | XXX | XXX |
EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
EBITDA Growth | 74% | XXX | XXX | XXX | XXX |
Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
Opex per Employee | $1.3M | XXX | XXX | XXX | XXX |
S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
Opex to Revenue | n/a | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
EV/Revenue | EV/EBITDA | |||||
---|---|---|---|---|---|---|
2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Celcuity acquired XXX companies to date.
Last acquisition by Celcuity was XXXXXXXX, XXXXX XXXXX XXXXXX . Celcuity acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiplesAcquired Company | EV | EV/Revenue | EV/EBITDA |
---|---|---|---|
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign UpWhen was Celcuity founded? | Celcuity was founded in 2011. |
Where is Celcuity headquartered? | Celcuity is headquartered in United States of America. |
How many employees does Celcuity have? | As of today, Celcuity has 87 employees. |
Who is the CEO of Celcuity? | Celcuity's CEO is Mr. Brian F. Sullivan. |
Is Celcuity publicy listed? | Yes, Celcuity is a public company listed on NAS. |
What is the stock symbol of Celcuity? | Celcuity trades under CELC ticker. |
When did Celcuity go public? | Celcuity went public in 2017. |
Who are competitors of Celcuity? | Similar companies to Celcuity include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
What is the current market cap of Celcuity? | Celcuity's current market cap is $369M |
What is the current EBITDA of Celcuity? | Celcuity's last 12-month EBITDA is -$124M. |
What is the current EV/EBITDA multiple of Celcuity? | Current EBITDA multiple of Celcuity is -1.9x. |
Is Celcuity profitable? | Yes, Celcuity is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.